1 / 24

Presenter: clerk 陳豪宏 Advisor: 柳景豑 醫師

Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Presenter: clerk 陳豪宏 Advisor: 柳景豑 醫師. Author. Jost B. Jonas Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University of Heidelberg, Germany.

efrat
Download Presentation

Presenter: clerk 陳豪宏 Advisor: 柳景豑 醫師

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Intravitreal triamcinolone acetonidefor treatment of intraocularoedematous and neovascular diseases Presenter: clerk 陳豪宏 Advisor: 柳景豑 醫師

  2. Author • Jost B. Jonas • Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University of Heidelberg, Germany

  3. Abstract-Usage 1 • Intravitreal triamcinolone acetonide (IVTA) for • intraocular neovascular and oedematous diseases. • Best response in visual acuity (VA) for Intraretinal oedematous diseases: • diffuse diabetic macular oedema • branch retinal vein occlusion • central retinal vein occlusion • pseudophakic cystoid macular oedema. • Non-infectious uveitis • acute or chronic sympathetic ophthalmia • Adamantiadis–Behcet’s disease • VA increased • intraocular inflammation decreased.

  4. Abstract-Usage 2 • angiostatic therapy • iris neovascularization • proliferative ischaemic retinopathies • adjunct therapy for • exudative age-related macular degeneration(AMD) • (in combination with photodynamic therapy) • For hypotony: • increase in IOP and may stabilize the eye.

  5. Abstract-Complications • secondary ocular hypertension 40% • medically uncontrollable high IOP • ->antiglaucomatous surgery in 1–2% • posterior subcapsular cataract and nuclear cataract • -> cataract surgery in 15–20% for elderly within 1 year • postoperative infectious endophthalmitis(1/1000) • non-ID endophthalmitis • pseudo-endophthalmitis with TA in AC.

  6. Abstract-Combo and duration • can be combined with other intraocular surgeries • cataract surgery particularly in eyes with iris neovascularization. • Cataract surgery performed some months after • -> no markedly elevated complication rate. • The injection maybe repeated. • In non-vitrectomized eyes, the duration of the effect and side-effects of a single IVTA: • 6–9 months (with 20 mg) • 2–4 months (with 4 mg).

  7. Introduction • The abnormal proliferation of IO Cells is often accompanied and stimulated by intraocular inflammation. • defects in the blood–retina barrier due to capillary leakage • -> accumulation of fluid in the intraretinal and subretinal spaces of the macula -> impaired vision.

  8. The steroids can… • reduce intraocular inflammation • tighten the capillary walls • suppress proliferation of cells

  9. The steroids have been used to… • topically as drops • given systemically • injected into the subconjunctival or sub-Tenon space. • Not enough IO concentration to achieve a therapeutic level • the systemic side-effects too pronounced for a prolonged treatment.

  10. to overcome these limitations… • IV application • to locally suppress IO inflammation • To reduce proliferation of cells • Soluble cortisone-> easy washout-> • Machemer(1996): triamcinolone acetonide (crystalline) • Many other clinical uses were studied and been reported using IVTA

  11. For Exudative AMD: • Recent estimates: about 70~90% of all verteporfinphotodynamic treatments for exudative MD are combinedwith IVTA. • Diffuse diabetic macular edema and • Proliferative diabetic retinopathy: • Recent studies: temporarily increase VA for diffuse diabetic macular edema

  12. For Diffuse DM macular edema and Proliferative DM retinopathy: • IVTA -> NO clinically significant serum concentration shortly after IVI of about 20 mg TA • Agrees with: clinical observations: no marked metabolic influence. • sub-Tenon method: less invasive. • A recent study: IVTA -> higher concentrations than sub-Tenon application.

  13. vitrectomy for proliferate DM vitreoretinopathy combined with IVTA • IVTA -> no higher postoperative complications rate. • It had not shown a marked therapeutic benefit.

  14. Vitrectomy combined with IVTA to visualize membranes and vitreousbody • Several studies: using TA during vitrectomy may facilitate both: • removal of the epiretinal membrane around the macular hole • separation of the residual vitreous cortex from the retina in highly myopic eyes with retinal detachment.

  15. Cataract surgery in eyes with iris neovascularization combined with IVTA • A study: IVTA may be a useful adjunctive treatment tool in eyes with iris neovascularization undergoing cataract surgery. • VA increased • without additional retinal ablative treatments, iris neovascularization markedly regressed

  16. For pseudophakic CME • In some studies: For persistent pseudophakic CME: increase in VA from 0.26±0.13 to a mean best VA of 0.60±0.19. • The increase in VA was statistically independent of the time interval of the surgery and IVTA.

  17. For retinal vein occlusions • For BRVO: Some studies: IVTA may be helpful in patients not responding to laser photocoagulation. • For CRVO: Some studies: • benefit from IVTA in terms of VA and macular edema for non-ischemic CRVO. • direct or indirect anti-angiogenic effect.

  18. For Uveitis • Based on the clinical experience gathered for the use of IVTA for other indications, TA has also been applied in eyes with chronic therapy-resistant uveitis.

  19. Other conditions: • ocular ischemic syndromes • CME due to retinitis pigmentosa • foveal telangiectasia • Progressive ocular hypotony

  20. Complications of IVTA • Secondary ocular hypertension • Secondary steroid-induced, open-angle glaucoma • Post-injection endophthalmitis • Post-injection pseudo-endophthalmitis • Rhegmatogenous retinal detachment • Post-injection, steroid-induced cataract • Central serous chorioretinopathy • Toxic effects

  21. Pharmacokinetics • Considerably higher vitreous concentrations of TA were achieved after IVI than after sub-Tenon injection. • IV conc. of TA were detectable up to 2.75 months after a single 4 mg injection in non-vitrectomized eyes.

  22. Pharmacokinetics II • found in aqueous humour and in silicone oil up to 1.5 years after IVI. • In vitrectomized eyes, the turnover rate of IVTA is considerably shorter than in nonvitrectomized eyes.

  23. Conclusion • IVTA -> new avenues for the treatment of intraocular edematous and neovascular diseases. • Great caution needed. • Long term experience not yet available. • many open questions still unanswered. (ex: dosage, best mode of application, other possible complications, among others.)

  24. End • Thank you.

More Related